Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine [Seeking Alpha]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Seeking Alpha
SummaryBioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's COVID-19 vaccine in China.Biogen announced a $2 billion blockbuster deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.Nanjing Simcere Pharma in-licensed Greater China rights to trilaciclib from North Carolina's GI Therapeutics in a $170 million agreement.COVID-19 PandemicBioKangtai (SHZ: 300601), a Guangdong vaccine company, in-licensed(NYSE:AZNShanghai Fosun Pharma (SHA: 600196; HK; 02196)reported(NASDAQ:BNTXPFEDeals and FinancingsBIIBDNLISherpa Healthcare Partners of Beijing closed its first US dollar fund with $200 million in capital, which Sherpa said was oversubscribed. The Oregon Public Employees System (PERS) committed $100 million of the total. Sherpa will focus on early- to growth-stage investments in biotech, biopharma, medical device and medical service companies in both China and the US. It has already completed investments in eight
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024PR Newswire
- Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67% [Yahoo! Finance]Yahoo! Finance
- HiLabs Announces Closing of $39 Million Series B Financing to Advance its AI-powered Data Management Solutions for Healthcare Organizations [Yahoo! Finance]Yahoo! Finance
DNLI
Earnings
- 2/27/24 - Miss
DNLI
Sec Filings
- 3/22/24 - Form S-3ASR
- 3/19/24 - Form 4
- 3/1/24 - Form D
- DNLI's page on the SEC website